![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
Disney
DIS
Amazon
AMZN
Netflix
NFLX
Cisco
CSCO
Adobe
ADBE
US Stock MarketDetailed Quotes
CTXR Citius Pharmaceuticals
- 1.5800
- -0.2100-11.73%
Close Mar 10 16:00 ET
- 1.5800
- 0.00000.00%
Post 20:01 ET
13.58MMarket Cap-0.27P/E (TTM)
1.8700High1.5800Low113.64KVolume1.8000Open1.7900Pre Close192.70KTurnover1.45%Turnover RatioLossP/E (Static)8.59MShares26.750052wk High0.21P/B12.39MFloat Cap1.470052wk Low--Dividend TTM7.84MShs Float750.0000Historical High--Div YieldTTM16.20%Amplitude1.4700Historical Low1.6950Avg Price1Lot Size
Citius Pharmaceuticals Stock Forum
Sign in to post a comment
$Citius Pharmaceuticals (CTXR.US)$
Citius Pharmaceuticals Secures Critical J-Code for LYMPHIR as Cash Reserves Hit $1.1M
Citius Pharmaceuticals Secures Critical J-Code for LYMPHIR as Cash Reserves Hit $1.1M
1
2
$Citius Pharmaceuticals (CTXR.US)$
Medicare Breakthrough: Citius's Cancer Drug LYMPHIR Gets Crucial Insurance Code - Major Win for CTCL Patients
Medicare Breakthrough: Citius's Cancer Drug LYMPHIR Gets Crucial Insurance Code - Major Win for CTCL Patients
1
$Citius Pharmaceuticals (CTXR.US)$ $Citius Oncology (CTOR.US)$ Reuters· just
Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for Lymphir by Centers for Medicare and Medicaid Services
Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for Lymphir by Centers for Medicare and Medicaid Services
5
$Citius Pharmaceuticals (CTXR.US)$
Citius Pharmaceuticals Advances LYMPHIR Launch Plans for Breakthrough CTCL Treatment
Citius Pharmaceuticals Advances LYMPHIR Launch Plans for Breakthrough CTCL Treatment
3
$Citius Pharmaceuticals (CTXR.US)$ $Citius Oncology (CTOR.US)$ Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025
PR Newswire· 4 mins ago
PR Newswire· 4 mins ago
2
$Citius Pharmaceuticals (CTXR.US)$ $Citius Oncology (CTOR.US)$
Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025
Tuesday, 7th January at 8:08 am
CRANFORD, N.J., Jan. 7, 2025 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (NASDAQ: CTXR) and its oncology-focused subsidiary, Citius Oncology (NASDAQ: CTOR), today announced significant progress in preparations for the commercial launch of LYMPHIR™, an i...
Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025
Tuesday, 7th January at 8:08 am
CRANFORD, N.J., Jan. 7, 2025 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (NASDAQ: CTXR) and its oncology-focused subsidiary, Citius Oncology (NASDAQ: CTOR), today announced significant progress in preparations for the commercial launch of LYMPHIR™, an i...
$Citius Pharmaceuticals (CTXR.US)$
The engagement of Jefferies as a financial advisor is a strategically significant move that could reshape Citius Oncology's future. Jefferies' strong track record in healthcare M&A and their expertise in orchestrating deals averaging $500M-$2B in the biotech sector positions them well to explore value-maximizing opportunities. With LYMPHIR™ recently FDA-approved and ready for commercialization, the timing aligns perfectly with...
The engagement of Jefferies as a financial advisor is a strategically significant move that could reshape Citius Oncology's future. Jefferies' strong track record in healthcare M&A and their expertise in orchestrating deals averaging $500M-$2B in the biotech sector positions them well to explore value-maximizing opportunities. With LYMPHIR™ recently FDA-approved and ready for commercialization, the timing aligns perfectly with...
6
$Citius Pharmaceuticals (CTXR.US)$
Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic Alternatives
Monday, 6th January at 7:50 am
CRANFORD, N.J., Jan. 6, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or "the Company") (NASDAQ: CTOR), a majority-owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (NASDAQ: CTXR), today announced that it has retained Jefferies LLC as its exclusive financial advisor to assist in evaluating strategi...
Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic Alternatives
Monday, 6th January at 7:50 am
CRANFORD, N.J., Jan. 6, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or "the Company") (NASDAQ: CTOR), a majority-owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (NASDAQ: CTXR), today announced that it has retained Jefferies LLC as its exclusive financial advisor to assist in evaluating strategi...
18
11
No comment yet
Trending Stocks
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
萬軍無兵策天鳳 : Summary: There is no hope left.![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")
71079745 萬軍無兵策天鳳 : There is hope, there is hope, do not be too pessimistic, we simply won't buy it.